1036027-60-7 Usage
Molecular Structure
1H-Pyrrolo[2,3-b]pyridine core with a trifluoromethyl group at the 5-position, a dioxaborolane group at the 3-position, a sulfonyl group at the 1-position, and a 4-methylphenyl group attached to the sulfonyl group.
Functional Groups
Trifluoromethyl (CF3), sulfonyl, dioxaborolane, and 4-methylphenyl groups.
Potential Applications
Organic synthesis, pharmaceuticals, and materials science.
Trifluoromethyl (CF3)
Can improve pharmacokinetic properties, metabolic stability, and lipophilicity of molecules.
Sulfonyl
Can enhance molecular stability and act as a leaving group in certain reactions.
Dioxaborolane
Boron-containing moiety that can participate in various chemical reactions, such as Suzuki-Miyaura cross-coupling.
4-Methylphenyl
Can influence the electronic properties and steric hindrance of the molecule.
Check Digit Verification of cas no
The CAS Registry Mumber 1036027-60-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,6,0,2 and 7 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1036027-60:
(9*1)+(8*0)+(7*3)+(6*6)+(5*0)+(4*2)+(3*7)+(2*6)+(1*0)=107
107 % 10 = 7
So 1036027-60-7 is a valid CAS Registry Number.
1036027-60-7Relevant articles and documents
INHIBITORS OF INFLUENZA VIRUSES REPLICATION
-
Page/Page column 111, (2013/03/26)
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.